Total Payments
$332,239
2024 Payments
$41,942
Companies
36
Transactions
321
Medicare Patients
707
Medicare Billing
$108,534
Payment Breakdown by Category
Consulting$268,695 (80.9%)
Research$23,494 (7.1%)
Other$17,540 (5.3%)
Travel$15,562 (4.7%)
Food & Beverage$6,936 (2.1%)
Education$12.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $268,695 | 102 | 80.9% |
| Unspecified | $23,494 | 15 | 7.1% |
| Travel and Lodging | $15,562 | 79 | 4.7% |
| Honoraria | $11,930 | 7 | 3.6% |
| Food and Beverage | $6,936 | 112 | 2.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,610 | 5 | 1.7% |
| Education | $12.00 | 1 | 0.0% |
Payments by Type
General
$308,745
306 transactions
Research
$23,494
15 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech, Inc. | $50,287 | 43 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $48,700 | 72 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $26,561 | 26 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $25,409 | 17 | $0 (2021) |
| PFIZER INC. | $21,058 | 11 | $0 (2024) |
| Foundation Medicine, Inc. | $12,793 | 11 | $0 (2020) |
| Millennium Pharmaceuticals, Inc. | $11,628 | 7 | $0 (2017) |
| Janssen Biotech, Inc. | $10,156 | 9 | $0 (2024) |
| AstraZeneca UK Limited | $8,806 | 5 | $0 (2021) |
| Gilead Sciences, Inc. | $8,623 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $41,942 | 41 | Acrotech Biopharma Inc. ($5,430) |
| 2023 | $45,369 | 45 | Genentech, Inc. ($12,365) |
| 2022 | $24,386 | 24 | Genentech USA, Inc. ($4,574) |
| 2021 | $42,378 | 22 | Genentech, Inc. ($6,980) |
| 2020 | $56,753 | 46 | Genentech, Inc. ($12,135) |
| 2019 | $63,855 | 70 | AstraZeneca Pharmaceuticals LP ($29,279) |
| 2018 | $22,042 | 43 | AstraZeneca Pharmaceuticals LP ($7,619) |
| 2017 | $35,513 | 30 | Millennium Pharmaceuticals, Inc. ($11,628) |
All Payment Transactions
321 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | Acrotech Biopharma Inc. | — | Consulting Fee | Cash or cash equivalent | $0.01 | General |
| 12/06/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: Oncology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,480.00 | General |
| 11/27/2024 | PFIZER INC. | LORBRENA (Drug) | Consulting Fee | Cash or cash equivalent | $1,705.00 | General |
| Category: ONCOLOGY | ||||||
| 11/23/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $32.86 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $102.40 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,220.00 | General |
| 11/12/2024 | Acrotech Biopharma Inc. | RYZNEUTA (Drug) | Consulting Fee | Cash or cash equivalent | $4,500.00 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | Genentech, Inc. | Tecentriq (Biological) | — | Cash or cash equivalent | $1,155.00 | Research |
| Study: 1LM SCLC Tecentriq Lurbinectedin • Category: BioOncology | ||||||
| 11/12/2024 | Acrotech Biopharma Inc. | RYZNEUTA (Drug) | Travel and Lodging | In-kind items and services | $56.38 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | Acrotech Biopharma Inc. | RYZNEUTA (Drug) | Food and Beverage | In-kind items and services | $15.98 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Acrotech Biopharma Inc. | RYZNEUTA (Drug) | Travel and Lodging | In-kind items and services | $474.95 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Acrotech Biopharma Inc. | RYZNEUTA (Drug) | Travel and Lodging | In-kind items and services | $219.69 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Acrotech Biopharma Inc. | RYZNEUTA (Drug) | Food and Beverage | In-kind items and services | $162.84 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,372.50 | General |
| Category: ONCOLOGY | ||||||
| 10/15/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $1,900.00 | General |
| 10/01/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $26.84 | General |
| Category: ONCOLOGY | ||||||
| 08/17/2024 | PFIZER INVESTMENT CO., LTD | — | Food and Beverage | In-kind items and services | $27.99 | General |
| 08/17/2024 | PFIZER INVESTMENT CO., LTD | — | Food and Beverage | In-kind items and services | $16.86 | General |
| 08/16/2024 | PFIZER INC. | — | Honoraria | Cash or cash equivalent | $650.00 | General |
| 08/14/2024 | PFIZER INVESTMENT CO., LTD | — | Food and Beverage | In-kind items and services | $13.21 | General |
| 08/02/2024 | PFIZER INVESTMENT CO., LTD | — | Food and Beverage | In-kind items and services | $13.05 | General |
| 06/21/2024 | PFIZER INC. | TUKYSA (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: TUKYSA CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 06/20/2024 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $4,610.53 | General |
| 06/12/2024 | Coherus Biosciences Inc. | — | Honoraria | Cash or cash equivalent | $1,200.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| 1LM SCLC Tecentriq Lurbinectedin | Genentech, Inc. | $5,940 | 4 |
| 1L SCLC ED | Genentech, Inc. | $3,884 | 2 |
| B FAST BLOOD FIRST ASSAY SCREENING TRIAL UMBRELLA STUDY BFAST BLOOD FIRST ASSAY SCREENING TRIAL | Genentech, Inc. | $3,420 | 2 |
| 1LM SCLC TECENTRIQ LURBINECTEDIN | Genentech, Inc. | $1,320 | 1 |
| QUALITATIVE RESEARCH TO EXPLORE THE EXPERIENCES OF PATIENTS WITH NON?SMALL CELL LUNG CANCER AND BRAIN METASTASES | Novartis Pharmaceuticals Corporation | $350.00 | 1 |
| TUKYSA CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 151 | 258 | $82,768 | $24,080 |
| 2022 | 5 | 175 | 287 | $91,057 | $25,601 |
| 2021 | 5 | 196 | 362 | $112,894 | $34,705 |
| 2020 | 5 | 185 | 312 | $103,099 | $24,148 |
Total Patients
707
Total Services
1,219
Medicare Billing
$108,534
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 67 | 122 | $41,968 | $12,287 | 29.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 44 | 64 | $16,320 | $4,574 | 28.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 45 | $11,250 | $3,663 | 32.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 27 | 27 | $13,230 | $3,557 | 26.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 57 | 108 | $37,152 | $10,671 | 28.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 62 | 103 | $26,265 | $7,198 | 27.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 29 | 29 | $14,210 | $3,743 | 26.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 15 | 35 | $8,750 | $2,774 | 31.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 12 | 12 | $4,680 | $1,215 | 26.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 66 | 152 | $52,288 | $16,923 | 32.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 69 | 124 | $31,620 | $9,144 | 28.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 30 | 30 | $14,700 | $4,340 | 29.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 18 | 43 | $10,750 | $3,411 | 31.7% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 13 | 13 | $3,536 | $886.13 | 25.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 84 | 188 | $64,672 | $14,470 | 22.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 29 | 29 | $14,210 | $3,374 | 23.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 20 | 39 | $9,750 | $2,748 | 28.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 41 | 45 | $11,475 | $2,630 | 22.9% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 11 | 11 | $2,992 | $925.94 | 30.9% |
About Dr. Thomas Stinchcombe, MD
Dr. Thomas Stinchcombe, MD is a Hematology & Oncology healthcare provider based in Chapel Hill, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1265510416.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Stinchcombe, MD has received a total of $332,239 in payments from pharmaceutical and medical device companies, with $41,942 received in 2024. These payments were reported across 321 transactions from 36 companies. The most common payment nature is "Consulting Fee" ($268,695).
As a Medicare-enrolled provider, Stinchcombe has provided services to 707 Medicare beneficiaries, totaling 1,219 services with total Medicare billing of $108,534. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location Chapel Hill, NC
- Active Since 11/02/2006
- Last Updated 08/02/2016
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1265510416
Products in Payments
- ALUNBRIG (Drug) $33,591
- TAGRISSO (Drug) $30,109
- LORBRENA (Drug) $19,103
- IMFINZI (Drug) $16,762
- TECENTRIQ (Biological) $15,025
- LIBTAYO (Biological) $15,016
- TABRECTA (Drug) $13,659
- MEKINIST (Drug) $8,068
- Alecensa (Biological) $7,901
- FOUNDATIONONE CDX (Device) $7,750
- RYBREVANT (Drug) $6,289
- Tecentriq (Biological) $6,090
- RYZNEUTA (Drug) $5,430
- FOUNDATIONACT (Device) $5,043
- Lenvima (Drug) $3,400
- PROMACTA (Drug) $3,144
- Kadcyla (Biological) $2,735
- Enhertu (Drug) $2,287
- OPDIVO (Biological) $2,240
- IMFINZI (Biological) $1,817
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Chapel Hill
Jared Weiss, M.d, M.D
Hematology & Oncology — Payments: $304,374
Hematology & Oncology $304,374
Dr. Nigel Key, Md, MD
Hematology & Oncology — Payments: $204,110
Hematology & Oncology $204,110
Dr. Alice Ma, Md, MD
Hematology & Oncology — Payments: $107,585
Hematology & Oncology $107,585
Dr. Norman Sharpless, Md, MD
Hematology & Oncology — Payments: $72,173
Hematology & Oncology $72,173
Dr. Lisa Carey, Md, MD
Hematology & Oncology — Payments: $58,769
Hematology & Oncology $58,769
Juneko Grilley-Olson, M.d, M.D
Hematology & Oncology — Payments: $36,255
Hematology & Oncology $36,255